Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine whether there is a statistical association between the changes from baseline in the levels of two cytokines interleukin (IL)-17A and IL-6 in the sputum of patients with chronic obstructive pulmonary disease (COPD) and the severity of acute exacerbations of COPD (AE-COPD). These sputum cytokine levels are taken as measures of the adaptive immune response (IL-17A) and the innate immune response (IL-6), respectively. Sputum will be collected either spontaneously or will be obtained by induction; cytokine levels will be measured by ELISA. The primary analysis, comparisons of sputum cytokine levels between clinical states, will be done using random effects modeling.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
40 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Recruited from pulmonary and general medicine clinics
Diagnosis of COPD (following American Thoracic Society guidelines) and/or chronic bronchitis
Forced Expiratory Volume in 1 second of less than 70% predicted value after bronchodilator
Current or former smokers with more than 20 pack-years
Daily productive cough for 3 months of the year for 2 consecutive years
At least one AE-COPD requiring medical attention in each year for the previous 3 years
Willingness to participate in follow-up studies defined in the protocol
Unstable cardiovascular disease
Other systemic disease in which survival of more than 2 years is unlikely
Mental incompetence or active psychiatric illness
Currently taking more than 20 mg/day of Prednisone
Participation in another experimental protocol within 6 weeks of study entry